IGF-1 LR3 (Long Arginine 3-IGF-1)
IGF-1 LR3 is an 83-amino-acid synthetic analog of IGF-1 with a 13-amino-acid N-terminal extension and Arg3 substitution. These modifications reduce IGFBP binding by over 100-fold, making it 2-3x more potent and up to 120x longer-acting than native IGF-1. It activates satellite cells for true muscle hyperplasia. Cancer risk is a real concern.
FormBlends Peptide Context
Reviewed May 14, 2026For Igf 1 Lr3 peptide guide, the useful question is what a reader can verify after leaving the page. The topic touches peptide therapy, so the content should help separate general education from anything that needs individualized clinician review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
IGF-1 LR3 authority snapshot
IGF-1 LR3 is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Early clinical or translational evidence
Regulatory reality
Not on Category 2 list; not affected by 2026 reclassification
Safety screen
Hypoglycemia (primary acute risk, must eat around injection time), Water retention and edema, Joint stiffness and pain should be reviewed in context.
This page currently connects to 5 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for IGF-1 LR3?
IGF-1 LR3 should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- IGF-1 LR3
- Category
- Muscle Growth
- Evidence
- Early clinical or translational evidence
- FDA status
- Not FDA approved
Step 1
Check evidence level
IGF-1 LR3's anabolic superiority over native IGF-1 was established by Tomas et al. (Biochem J 1992) in catabolic rat models. Cancer risk association comes from Key et al. (Lancet Oncology 2010, PMID: 20472501), a pooled analysis of ~400,000 subjects showing modest but statistically significant links between circulating IGF-1 and colorectal, breast, and prostate cancer. No human clinical trials of LR3 exist, only preclinical and mechanistic data.
Review evidenceStep 2
Screen safety context
Hypoglycemia (primary acute risk, must eat around injection time), Water retention and edema, Joint stiffness and pain should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessLast updated: April 6, 2026
Typical Dosage
20-50 mcg/day subcutaneous injection. Start at 20 mcg, increase to 40-50 mcg if tolerated. Cycle 4-6 weeks on, 2-4 weeks off. Must eat within 30 minutes of injection (hypoglycemia risk). Post-workout or split AM/PM timing.
Administration
Subcutaneous injection
Typical Cost
$60-120 per 1 mg vial (research); $200-400/month estimated clinic cost
FDA Status
Not FDA Approved
Half-Life
20-30 hours (versus 12-15 hours for native IGF-1). Functionally active up to 120x longer than native IGF-1 due to minimal IGFBP binding.
Onset of Action
Anabolic effects begin within hours. Measurable muscle composition changes require weeks of dosing. Hypoglycemia can occur within 30-60 minutes of injection.
Bioavailability
High subcutaneous. Over 100-fold lower IGFBP affinity means approximately 99% circulates freely versus less than 1% for native IGF-1.
About IGF-1 LR3
IGF-1 LR3 (Long Arginine 3-IGF-1) is an 83-amino-acid synthetic analog of native IGF-1 (70 amino acids). CAS number: 946870-92-4. Molecular weight: 9,117.5 Da. The molecule has two modifications that make it far more potent than native IGF-1. First, a 13-amino-acid extension (MFPAMPLLSLFVN) at the N-terminus sterically blocks binding to IGF binding proteins (IGFBPs). Second, the glutamic acid at position 3 is replaced with arginine (Arg3), further reducing IGFBP affinity by over 100-fold. This matters because native IGF-1 is approximately 99% bound to IGFBPs at any given moment. The binding proteins sequester it, limit its bioactivity, and regulate its clearance. IGF-1 LR3 bypasses this entire regulatory mechanism. It circulates freely, remains bioactive for 20-30 hours (versus 12-15 for native IGF-1), and delivers sustained IGF-1R activation that native IGF-1 simply cannot. The anabolic mechanism is the real draw. IGF-1 LR3 doesn't just make existing muscle fibers bigger (hypertrophy). It directly activates satellite cells, the muscle stem cells that can differentiate into new muscle fibers. This means true hyperplasia, more actual muscle fibers, not just larger ones. Tomas et al. (Biochemical Journal 1992) showed LR3 was more anabolic than native IGF-1 even in dexamethasone-treated (catabolic) rats. But the cancer question can't be ignored. The same property that makes LR3 good for muscle (prolonged, unbound IGF-1R activation) also makes it concerning for cancer. IGF-1R activation drives cell proliferation broadly, not just in muscle. Key et al. (Lancet Oncology 2010, PMID: 20472501) pooled data from approximately 400,000 subjects and found statistically significant associations between circulating IGF-1 levels and colorectal, breast, and prostate cancer. These associations are with normal variation in native IGF-1, which is mostly protein-bound and self-limiting. LR3 provides supraphysiological, unbound IGF-1R activation that bypasses the body's normal regulatory safety net. The standard protocol uses 20-50 mcg/day subcutaneous, cycled 4-6 weeks on and 2-4 weeks off. You must eat within 30 minutes of injection because the insulin-like glucose uptake effect creates real hypoglycemia risk. The only FDA-approved recombinant IGF-1 is mecasermin (Increlex), which is native IGF-1 for severe IGF-1 deficiency in children. LR3 has never been in clinical trials.
How IGF-1 LR3 Works
IGF-1 LR3 is a full agonist of the IGF-1 receptor (IGF-1R). It drives muscle protein synthesis through the PI3K/Akt/mTOR pathway, inhibits muscle breakdown through PI3K/Akt/GSK3-beta, and directly activates satellite cells (muscle stem cells) for true hyperplasia (new fiber formation, not just fiber enlargement). It also increases glucose uptake (insulin-like effect). The 13-amino-acid N-terminal extension sterically blocks IGFBP binding, and the Arg3 substitution further reduces IGFBP affinity. Together, these keep LR3 circulating freely instead of being sequestered like native IGF-1 (which is ~99% protein-bound).
Receptor targets:
Benefits
- 2-3x more potent than native IGF-1 for protein synthesis
- Up to 120x longer functional duration due to reduced IGFBP binding
- Activates satellite cells for true muscle fiber hyperplasia
- Anti-catabolic (preserves muscle during caloric restriction)
- More anabolic than native IGF-1 in catabolic states (Tomas et al., 1992)
What Does the Research Say?
IGF-1 LR3's anabolic superiority over native IGF-1 was established by Tomas et al. (Biochem J 1992) in catabolic rat models. Cancer risk association comes from Key et al. (Lancet Oncology 2010, PMID: 20472501), a pooled analysis of ~400,000 subjects showing modest but statistically significant links between circulating IGF-1 and colorectal, breast, and prostate cancer. No human clinical trials of LR3 exist, only preclinical and mechanistic data.
Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats
Biochemical Journal, 1992 · DOI
LR3 IGF-1 is more anabolic than native IGF-1 in catabolic states due to reduced IGFBP sequestration, establishing the superior potency of the LR3 variant
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
Lancet Oncology, 2010 · DOI · PubMed
Pooled analysis of approximately 400,000 subjects confirmed modest but statistically significant association between circulating IGF-1 levels and risk of hormone-sensitive cancers
PubMed evidence trail
Research sources used to frame this page
For IGF-1 LR3, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Potential Side Effects
- Hypoglycemia (primary acute risk, must eat around injection time)
- Water retention and edema
- Joint stiffness and pain
- Headaches at higher doses
- Insulin resistance with prolonged use
- Organ growth (organomegaly) theoretical risk at high doses
- Cancer risk: elevated IGF-1 promotes cell division (epidemiological association with colorectal, breast, prostate cancer)
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Insulin | Both IGF-1 LR3 and insulin increase glucose uptake. Combined use creates serious hypoglycemia risk. | major |
| GH and GH secretagogues | GH stimulates endogenous IGF-1 production. Adding exogenous LR3 pushes total IGF-1R activation to supraphysiological levels, amplifying cancer risk. | major |
| Oral hypoglycemics (metformin, sulfonylureas) | Additive blood sugar-lowering effect. Monitor glucose closely. | moderate |
Who Is IGF-1 LR3 For?
Women
Women have lower baseline IGF-1 and may be more sensitive to exogenous LR3. Breast cancer risk association with elevated IGF-1 is particularly relevant (Key et al. 2010). Contraindicated in women with BRCA mutations or breast cancer history.
Adults Over 50
Natural IGF-1 declines with age (somatopause). Theoretical appeal for sarcopenia, but cancer risk is especially concerning in older populations with higher baseline cancer incidence. Careful risk-benefit analysis required.
Athletes
Prohibited at all times by WADA. IGF-1 and all analogs are banned under S2. WADA has issued specific statements on IGF-1 detection methods.
Regulatory Status
FDA Approved
No
Compounding Legal
No
2026 HHS Status
Not on Category 2 list; not affected by 2026 reclassification
IGF-1 LR3 was not on the FDA Category 2 peptide list from the 2023 crackdown. It is not available through standard compounding pharmacies for human use. Research chemical suppliers only.
Last verified: 2026-04-06
Stacking Options
IGF-1 LR3 is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get IGF-1 LR3 from FormBlends
Pharmaceutical-grade igf-1 lr3 with free physician consultation.
View Product DetailsFind a IGF-1 LR3 Clinic Near You
Browse peptide therapy clinics in your area that offer igf-1 lr3 treatments.
Find Peptide Clinics